[1] Diehm, C., Trampisch, H. J., Lange, S., & Schmidt, C. (1996). Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. The Lancet, 347(8997), 292-294.
[2] Vidal. Phytothérapie : Mélilot. https://www.vidal.fr/parapharmacie/phytotherapie-plantes/melilot-melilotus-officinalis.html.
[3] Motte, S. (2022). Quelle est la place de la diosmine dans le traitement de l’insuffisance veineuse chronique ? Revue Médicale de Bruxelles, vol. 43-6.
[4] Rațiu, S., Mariș, M. I., Furdui-Lința, A. V., Sima, L. V., Bratu, T. I., Sturza, A., ... & Crețu, O. M. (2025). Oxidative stress in the pathophysiology of chronic venous disease: an overview. Antioxidants, 14(8), 989.
[5] Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail. Vitamine C. https://www.anses.fr/fr/content/vitamine-c.
[6] Manon‐Jensen, T., Kjeld, N. G., & Karsdal, M. A. (2016). Collagen‐mediated hemostasis. Journal of Thrombosis and Haemostasis, 14(3), 438-448.
[7] May, J. M., & Harrison, F. E. (2013). Role of vitamin C in the function of the vascular endothelium. Antioxidants & redox signaling, 19(17), 2068-2083.
[8] Montecinos, V., Guzmán, P., Barra, V., Villagrán, M., Muñoz-Montesino, C., Sotomayor, K., ... & Vera, J. C. (2007). Vitamin C is an essential antioxidant that enhances survival of oxidatively stressed human vascular endothelial cells in the presence of a vast molar excess of glutathione. Journal of Biological Chemistry, 282(21), 15506-15515.
[9] Pancorbo1ABCDEFG, D., Vazquez1ABDEF, C., & Fletcher2BDEF, M. A. (2008). Vitamin C-lipid metabolites: uptake and retention and effect on plasma C-reactive protein and oxidized LDL levels in healthy volunteers. Med Sci Monit, 14(11), 551.
[10] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Scientific Opinion on the substantiation of health claims related to vitamin E and protection of DNA, proteins and lipids from oxidative damage (ID 160, 162, 1947), maintenance of the normal function of the immune system (ID 161, 163), maintenance of normal bone (ID 164), maintenance of normal teeth (ID 164), maintenance of normal hair (ID 164), maintenance of normal skin (ID 164), maintenance of normal nails (ID 164), maintenance of normal cardiac function (ID 166), maintenance of normal vision by protection of the lens of the eye (ID 167), contribution to normal cognitive function (ID 182, 183), regeneration of the reduced form of vitamin C (ID 203), maintenance of normal blood circulation (ID 216) and maintenance of a normal scalp (ID 2873) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010; 8(10):1816. [30 pp.].
[11] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to selenium and protection of DNA, proteins and lipids from oxidative damage (ID 277, 283, 286, 1289, 1290, 1291, 1293, 1751), function of the immune system (ID 278), thyroid function (ID 279, 282, 286, 1289, 1290, 1291, 1293), function of the heart and blood vessels (ID 280), prostate function (ID 284), cognitive function (ID 285) and spermatogenesis (ID 396) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal 2009; 7(9):1220. [24 pp.].
[12] Haleng, Pincemail, Defraigne, Charlier, Chapelle. 2007. Le stress oxydant. Rev Med Liège; 62 : 10 : 628-638.
[13] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to vitamin B6 and protein and glycogen metabolism (ID 65, 70, 71), function of the nervous system (ID 66), red blood cell formation (ID 67, 72, 186), function of the immune system (ID 68), regulation of hormonal activity (ID 69) and mental performance (ID 185) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal 2009; 7(9):1225 [20 pp.].
[14] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to vitamin B6 and protein and glycogen metabolism (ID 65, 70, 71), function of the nervous system (ID 66), red blood cell formation (ID 67, 72, 186), function of the immune system (ID 68), regulation of hormonal activity (ID 69) and mental performance (ID 185) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal 2009; 7(9):1225 [20 pp.].[15] Fédération française de cardiologie. Insuffisance veineuse : les situations à risque. https://www.fedecardio.org/je-m-informe/insuffisance-veineuse-les-situations-a-risque/.